ENDO PHARM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ENDO PHARM, and when can generic versions of ENDO PHARM drugs launch?
ENDO PHARM has fifteen approved drugs.
There are sixteen US patents protecting ENDO PHARM drugs.
There are two hundred and two patent family members on ENDO PHARM drugs in thirty-three countries.
Summary for ENDO PHARM
International Patents: | 202 |
US Patents: | 16 |
Tradenames: | 12 |
Ingredients: | 10 |
NDAs: | 15 |
Patent Litigation for ENDO PHARM: | See patent lawsuits for ENDO PHARM |
PTAB Cases with ENDO PHARM as petitioner: | See PTAB cases with ENDO PHARM as petitioner |
PTAB Cases with ENDO PHARM as patent owner: | See PTAB cases with ENDO PHARM as patent owner |
Drugs and US Patents for ENDO PHARM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Pharms | SYMMETREL | amantadine hydrochloride | TABLET;ORAL | 018101-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021610-005 | Feb 29, 2008 | DISCN | Yes | No | 8,808,737 | ⤷ Sign Up | ⤷ Sign Up | ||||
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-003 | Dec 9, 2011 | DISCN | Yes | No | 8,871,779 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-002 | Dec 9, 2011 | DISCN | Yes | No | 8,114,383 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Endo Pharms | SYMMETREL | amantadine hydrochloride | SYRUP;ORAL | 016023-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ENDO PHARM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-002 | Dec 9, 2011 | 8,075,872 | ⤷ Sign Up |
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021610-007 | Feb 29, 2008 | 8,309,112 | ⤷ Sign Up |
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021610-003 | Jun 22, 2006 | 5,662,933 | ⤷ Sign Up |
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-001 | Dec 9, 2011 | 8,329,216 | ⤷ Sign Up |
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-005 | Dec 9, 2011 | 8,309,122 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ENDO PHARM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Tablets | 5 mg, 10 mg, 20 mg and 40 mg | ➤ Subscribe | 2007-11-23 |
➤ Subscribe | Extended-release Tablets | 30 mg | ➤ Subscribe | 2008-06-12 |
➤ Subscribe | Extended-release Tablets | 7.5 mg and 15 mg | ➤ Subscribe | 2008-05-29 |
➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
International Patents for ENDO PHARM Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Argentina | 049083 | ⤷ Sign Up |
Australia | 2006210145 | ⤷ Sign Up |
South Korea | 101160813 | ⤷ Sign Up |
Germany | 10336400 | ⤷ Sign Up |
Cyprus | 1107644 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.